Arab World vs Sierra Leone: Access to anti-retroviral drugs, female
Arab World
48.4%
in 2024
Sierra Leone
95.0%
in 2024
Arab World rank
16th
Sierra Leone rank
19th
Access to anti-retroviral drugs, female over time
- Arab World
- Sierra Leone
How they compare
Sierra Leone currently reports 95.0% against 48.4% in Arab World, a difference of 46.6%.
That makes Sierra Leone's figure about 2.0 times Arab World's.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Arab World ahead.
Arab World ranks 16th and Sierra Leone ranks 19th of 19 groups.
Across the 3 decades both report, Arab World averaged higher in 1 and Sierra Leone in 2.
Head to head by decade
| Decade | Arab World | Sierra Leone | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 4.7% | 1.5% | 3.2% | Arab World |
| 2010s | 28.0% | 28.4% | 0.4% | Sierra Leone |
| 2020s | 46.9% | 80.4% | 33.5% | Sierra Leone |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Arab World or Sierra Leone?
- Sierra Leone, at 95.0% against 48.4% in Arab World as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Arab World and Sierra Leone?
- 46.6%, with Sierra Leone ahead.
- How many years of comparable data are there for Arab World and Sierra Leone?
- 25 years are reported by both, from 2000 to 2024.
- How do Arab World and Sierra Leone rank globally for access to anti-retroviral drugs, female?
- Arab World ranks 16th and Sierra Leone ranks 19th of 19 groups.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.